middle.news
FDA Lifts Clinical Hold on Neurizon’s NUZ-001, Paving Way for ALS Trial
9:52am on Wednesday 29th of October, 2025 AEDT
•
Biotechnology
Read Story
FDA Lifts Clinical Hold on Neurizon’s NUZ-001, Paving Way for ALS Trial
9:52am on Wednesday 29th of October, 2025 AEDT
Key Points
FDA lifts clinical hold on NUZ-001, enabling entry into HEALEY ALS Platform Trial
Exclusive global licensing agreement signed with Elanco Animal Health
Positive 12-month safety and preliminary efficacy data from Open-Label Extension study
GMP manufacturing of NUZ-001 registration batches commenced at Catalent
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE